Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors

Fig. 3

Factors selection and nomogram construction based on peripheral-blood inflammatory-nutritional indices of severe irAEs. a The LASSO coefficient profiles of the candidate variables; b the optimal tuning parameter (lambda, λ) in the LASSO analysis selected with tenfold cross-validation via minimum criteria; c forest plot of multivariate analysis independent prognostic analysis of severe irAEs; d the “AdNLA” nomogram (based on age, change-dNLR, changeLMR and postALI) were constructed for severe irAEs prediction of aNSCLC patients receiving ICIs; e the ROC curve of the nomogram for severe irAEs; f calibration curves of the nomogram for severe irAEs; g decision curves analysis of the nomogram for severe irAEs. irAEs immune-related adverse events, change-dNLR change of derived-neutrophil–lymphocyte ratio, changeLMR change of lymphocyte-to-monocyte ratio, postALI post-treatment advanced lung cancer inflammation index

Back to article page